Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: Updated results of the multicenter consecutive GITMO trial

M. Ladetto*, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, V. Callea, C. Patti, P. Coser, A. Perrotti, M. Sorio, C. Boccomini, A. Pulsoni, C. Stelitano, R. Scimè, M. Boccadoro, R. Rosato, F. De Marco, M. Zanni, P. Corradini, C. Tarella

*Korrespondierende:r Autor:in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

20 Zitate (Scopus)

Abstract

This study provides an updated report of the consecutive multicenter Gruppo Italiano Trapianto Midollo Osseo trial employing an intensified, purging-free, total body irradiation-free, high-dose sequential chemotherapy schedule with peripheral blood stem cell autograft (i-HDS) in advanced-stage follicular lymphoma (FL). Special interest has been devoted to late toxicities and outcome in terms of molecular status. Ninety-two untreated FL patients aged ≤60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. Main findings are as follows: (1) 5.5-years overall survival projection of 80% (median follow-up: 68months), with no differences related to age-adjusted IPI score; (2) 46 (50%) of 92 patients presently in continuous complete remission; (3) projected long-term progression-free survival exceeding 80% for patients collecting PCR-negative stem cell harvests or achieving molecular remission within the first 2 years from the end of therapy; (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma. These results demonstrate that i-HDS is feasible, effective and safe even in terms of long-term outcome. As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy.

OriginalspracheEnglisch
Seiten (von - bis)1840-1847
Seitenumfang8
FachzeitschriftLeukemia
Jahrgang20
Ausgabenummer10
DOIs
PublikationsstatusVeröffentlicht - Okt. 2006
Extern publiziertJa

ASJC Scopus Sachgebiete

  • Hämatologie
  • Onkologie
  • Krebsforschung

Fingerprint

Untersuchen Sie die Forschungsthemen von „Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: Updated results of the multicenter consecutive GITMO trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren